|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Arthritis, Psoriatic | |||||
| Psoriasis | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Arthritis | |||||
| 3 | More general conditions related to this trial | ||||
| Bone Diseases | |||||
| Joint Diseases | |||||
| Musculoskeletal Diseases | |||||
| Skin Diseases | |||||
| Skin Diseases, Papulosquamous | |||||
| Spinal Diseases | |||||
| Spondylarthritis | |||||
| Spondylarthropathies | |||||
| 4 | Interventions listed in this trial | ||||
| fludarabine | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Fludarabine monophosphate | |||||
| 6 | More general drug interventions related to this trial | ||||
| Antimetabolites | |||||
| Antimetabolites, Antineoplastic | |||||
| Antineoplastic Agents | |||||
| Immunologic Factors | |||||
| Immunosuppressive Agents | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | |||||